Cynvenio Biosystems Joins Life Technologies’ Ion Certified Service Provider Program

CARLSBAD, Calif. and WESTLAKE VILLAGE, Calif. -- Dec. 20, 2013 -- Life Technologies Corporation (NASDAQ: LIFE) today announced that Cynvenio Biosystems, a molecular testing company focused on liquid biopsy assay development, has joined the Ion Certified Service Provider (CSP) program. Cynvenio’s LiquidBiopsy® technology is a proprietary platform for recovering circulating tumor cells at purity levels high enough to enable detection by next-generation sequencing. 
Service providers in the Ion CSP program are reviewed and qualified for membership by Life Technologies based on rigorous quality standards. The program has become one of the world’s largest networks of next generation-based sequencing service providers, representing some of the premier institutions in the life sciences industry. 
In addition to providing research-use-only (RUO) services under the Ion CSP program, Cynvenio has several development programs supported by the National Cancer Institute that are focused on finding cancer biomarkers in the blood.  These programs are aimed at developing fast, non-invasive methods for detecting and managing breast cancer and other adenocarcinomas (solid tumors).

"The capabilities of the Ion PGM™ System, in conjunction with the Ion AmpliSeq™ chemistry, enable Cynvenio to provide reliable sequencing of circulating tumor cells for oncology researchers and drug developers," said Paul Dempsey, Ph.D., chief science officer, Cynvenio. “Incorporating next-generation sequencing in liquid biopsy assay development is a milestone that’s enabled high-throughput molecular analysis. Now we can use increasingly larger molecular panels and get results to researchers within a week.”

Ion Reporter™ Software also contributes to the quick turnaround time Ion CSP member sites deliver. Ion Reporter™ Software, an easy-to-use bioinformatics solution, can deliver analyzed results in an easy-to-read report within hours after sequencing. The analysis data includes copy number variation and a list of mutations and associated annotations drawn from dozens of public databases. Additionally, customers can conveniently access their sequencing data through the web.

“The Ion CSP program is rapidly expanding in North America and Europe and we expect to soon have sites in the Asia Pacific region,” said Maneesh Jain, vice president of Marketing, Product and Program Management at Life Technologies. “The service provider program model allows customer samples to be processed quickly and easily to fit any size research project.” 
The Ion AmpliSeq™ assays, Ion Proton™ PGM Sequencer, and Ion Reporter™ Software are For Research Use Only. Not for use in diagnostic procedures.
About Cynvenio Biosystems
Cynvenio is a molecular testing company focused on the genomic analysis of tumor biomarkers in the bloodstream. The company’s LiquidBiopsy® real time molecular test is designed for industry and academic researchers to identify the presence of tumor-cell genetic mutations in whole blood. Founded in 2008, Cynvenio is headquartered in Westlake Village, Calif. (Los Angeles). LiquidBiopsy® is a registered trademark of Cynvenio Biosystems, Inc. For more information please visit

About Life Technologies 
Life Technologies Corporation (NASDAQ: LIFE) is a global biotechnology company that is committed to providing the most innovative products and services to leading customers in the fields of scientific research, genetic analysis and applied sciences. With a presence in more than 180 countries, the company's portfolio of 50,000 end-to-end solutions is secured by more than 5,000 patents and licenses that span the entire biological spectrum—scientific exploration, molecular diagnostics, 21st century forensics, regenerative medicine and agricultural research. Life Technologies has approximately 10,000 employees and had sales of $3.8 billion in 2012.
Life Technologies' Safe Harbor Statement
This press release includes forward-looking statements about our anticipated results that involve risks and uncertainties. Some of the information contained in this press release, including, but not limited to, statements as to industry trends and Life Technologies' plans, objectives, expectations and strategy for its business, contains forward-looking statements that are subject to risks and uncertainties that could cause actual results or events to differ materially from those expressed or implied by such forward-looking statements. Any statements that are not statements of historical fact are forward-looking statements. When used, the words "believe," "plan," "intend," "anticipate," "target," "estimate," "expect" and the like, and/or future tense or conditional constructions ("will," "may," "could," "should," etc.), or similar expressions, identify certain of these forward-looking statements. Important factors which could cause actual results to differ materially from those in the forward-looking statements are detailed in filings made by Life Technologies with the Securities and Exchange Commission. Life Technologies undertakes no obligation to update or revise any such forward-looking statements to reflect subsequent events or circumstances.

Life Technologies Contact:
Wes Conard